Ultrasound guided tattooing of axillary lymph nodes in breast cancer patients prior to neoadjuvant therapy, and identification of tattooed nodes at the time of surgery

ConclusionsTattooing of axillary LNs is safe and easily performed. Tattooing was helpful in identifying the marked LN in the majority of cases. This technique helps to ensure that metastatic LNs are identified and removed at surgery after NAT.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

ConclusionsThis study demonstrates that the ROLL procedure to identify clip-marked lymph nodes is feasible. This facilitates selective removal at surgery and may tailor axillary treatment in patients treated with NST.
Source: EJNMMI Research - Category: Radiology Source Type: research
Condition:   Breast Cancer Intervention:   Sponsor:   Sunnybrook Health Sciences Centre Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Sponsor:   Sunnybrook Health Sciences Centre Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Sponsor:   Sunnybrook Health Sciences Centre Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Increasing numbers of breast cancer patients receive neoadjuvant chemotherapy (NACT). We seek to investigate whether baseline mammographic and ultrasound features are associated with complete pathological resp...
Source: Cancer Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
AbstractBackgroundThe density of tumor-infiltrating lymphocytes (TIL) is a predictive factor for response to neoadjuvant systemic therapy (NAST) in breast cancer. High TIL density correlates with higher complete pathologic remission (pCR) in triple negative and HER2 positive breast cancer. Additionally, not only TIL density but also subsets of immune cells in tumor stroma seem to play an important role in cancer and immune cell interaction and response to chemotherapy. Our aim is to determine TIL density and expression of CD 20, CD3, CD8, PD-L1, FOXP3 and PGM1 on core biopsy specimen and find a correlation with pCR.Trial d...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis study confirms that ER PAS in ER-positive patients, measured before and after neoadjuvant endocrine therapy, has potential to predict and assess therapy response, and predict DFS.Legal entity responsible for the studyPhilips Electronics Nederland B.V., acting through its HealthWorks Molecular Pathway Dx.FundingHas not received any funding.DisclosureM. A. Inda: Full / Part-time employment: Philips Reseach. A. van de Stolpe: Full / Part-time employment, has Philips stocks: Philips Research. D. Keizer: Full / Part-time employment: Philips. D. Clout: Full / Part-time employment: Philips Reasearch. H. van Zon: F...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPreliminary results demonstrated a high DR supporting the feasibility of this approach, however, the FNR of TAD (4.4%) was higher than reported earlier (FNR = 2.0%, Caudle et al.). This is of great importance for postneoadjuvant treatment decisions in case of non-pCR and should be discussed.Clinical trial identificationNCT03102307; release date: April 5, 2017.Legal entity responsible for the studyKliniken Essen-Mitte.FundingHas not received any funding.DisclosureM. Reinisch: Honoraria (self): Pfizer, Novartis, Eli Lilly, Roche; Advisory / Consultancy: Roche, Daiichi Sankyo, Hexal, Eli Lilly, Novartis; Travel / A...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
We report on our experience of ultrasound (US)-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy (NAC) with clip and activated charcoal to guide axillary surgery in breast c...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
ConclusionsAx-pCR was more likely to be achieved in patients who were diagnosed with ER-negative and high-grade breast cancer and those with ycN0 and clinical CR at the primary site after NAC than among others. Among these patients, those with initially cN1/N2 might be good candidates for a deescalated treatment strategy after NAC.
Source: Surgery Today - Category: Surgery Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Men | Neoadjuvant Therapy | Surgery | Ultrasound